Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:ATAI NASDAQ:COAG NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.19+0.2%$6.12$3.56▼$8.40$1.53B0.583.33 million shs2.88 million shsATAIAtai Beckley$4.17+1.7%$4.21$2.04▼$6.75$1.51B1.65.23 million shs5.00 million shsCOAGHemab Therapeutics$28.75-1.4%$0.00$23.00▼$36.61$1.34BN/A263,077 shs134,975 shsLRMRLarimar Therapeutics$3.63-1.4%$3.84$2.71▼$6.42$382.29M0.831.87 million shs1.56 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.16%+5.99%+1.31%+8.79%+68.21%ATAIAtai Beckley+1.96%+2.46%-3.47%+17.80%+97.63%COAGHemab Therapeutics-1.37%+8.70%+11.05%+2,874,999,900.00%+2,874,999,900.00%LRMRLarimar Therapeutics-1.36%+2.54%+5.22%-25.15%+21.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.19+0.2%$6.12$3.56▼$8.40$1.53B0.583.33 million shs2.88 million shsATAIAtai Beckley$4.17+1.7%$4.21$2.04▼$6.75$1.51B1.65.23 million shs5.00 million shsCOAGHemab Therapeutics$28.75-1.4%$0.00$23.00▼$36.61$1.34BN/A263,077 shs134,975 shsLRMRLarimar Therapeutics$3.63-1.4%$3.84$2.71▼$6.42$382.29M0.831.87 million shs1.56 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.16%+5.99%+1.31%+8.79%+68.21%ATAIAtai Beckley+1.96%+2.46%-3.47%+17.80%+97.63%COAGHemab Therapeutics-1.37%+8.70%+11.05%+2,874,999,900.00%+2,874,999,900.00%LRMRLarimar Therapeutics-1.36%+2.54%+5.22%-25.15%+21.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$15.73154.08% UpsideATAIAtai Beckley 2.91Moderate Buy$16.00283.69% UpsideCOAGHemab Therapeutics 2.83Moderate Buy$41.4044.00% UpsideLRMRLarimar Therapeutics 3.10Buy$13.50271.90% UpsideCurrent Analyst Ratings BreakdownLatest LRMR, ATAI, ARDX, and COAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026COAGHemab Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/17/2026COAGHemab Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/8/2026ATAIAtai Beckley HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026ATAIAtai Beckley AegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.75N/AN/A$0.69 per share8.97ATAIAtai Beckley$4.09M375.37N/AN/A$0.69 per share6.04COAGHemab TherapeuticsN/AN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A11.05N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)ATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)COAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/ALRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)Latest LRMR, ATAI, ARDX, and COAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AATAIAtai BeckleyN/AN/AN/AN/AN/ACOAGHemab TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28ATAIAtai Beckley0.027.907.90COAGHemab TherapeuticsN/AN/AN/ALRMRLarimar TherapeuticsN/A4.294.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%ATAIAtai Beckley28.41%COAGHemab TherapeuticsN/ALRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%ATAIAtai Beckley26.80%COAGHemab TherapeuticsN/ALRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableATAIAtai Beckley80368.17 million269.50 millionOptionableCOAGHemab Therapeutics7246.71 millionN/AN/ALRMRLarimar Therapeutics30103.88 million99.21 millionOptionableLRMR, ATAI, ARDX, and COAG HeadlinesRecent News About These CompaniesLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Recommendation of "Buy" by AnalystsJune 16, 2026 | americanbankingnews.comJP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight RecommendationMay 28, 2026 | msn.comLarimar Therapeutics Reports First Quarter 2026 Financial and Business UpdateMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR)May 2, 2026 | theglobeandmail.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s AtaxiaApril 30, 2026 | markets.businessinsider.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaApril 30, 2026 | globenewswire.comWedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13March 27, 2026 | finance.yahoo.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 | globenewswire.com2 Breakout Stocks to Buy ImmediatelyMarch 8, 2026 | investorplace.comLRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?March 6, 2026 | zacks.comLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchMarch 4, 2026 | globenewswire.comLarimar Therapeutics price target raised to $12 from $11 at WedbushMarch 4, 2026 | finance.yahoo.comInsider Buying: Larimar Therapeutics (NASDAQ:LRMR) Director Buys $25,000,000.00 in StockMarch 3, 2026 | insidertrades.comLarimar Therapeutics: Deerfield entities buy $25m in stockMarch 3, 2026 | investing.comLarimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?February 28, 2026 | finance.yahoo.comLarimar Therapeutics stock falls 8% on upsized $100 million offeringFebruary 27, 2026 | in.investing.comWhy Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 22.49%February 25, 2026 | aaii.comALarimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics stock surges on FDA breakthrough statusFebruary 24, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLRMR, ATAI, ARDX, and COAG Company DescriptionsArdelyx NASDAQ:ARDX$6.19 +0.01 (+0.16%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$6.27 +0.08 (+1.29%) As of 07:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Atai Beckley NASDAQ:ATAI$4.17 +0.07 (+1.71%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$4.22 +0.05 (+1.22%) As of 07:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Hemab Therapeutics NASDAQ:COAG$28.75 -0.40 (-1.37%) As of 06/24/2026 04:00 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Larimar Therapeutics NASDAQ:LRMR$3.63 -0.05 (-1.36%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$3.69 +0.06 (+1.76%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
